Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Not all profitable companies are created equal, and that’s why we built StockStory - to help you find the ones that truly shine bright. That said, here are three profitable companies that don’t make the cut and some better opportunities instead.
Teradyne (TER)
Trailing 12-Month GAAP Operating Margin: 30.2%
Sporting most major chip manufacturers as its customers, Teradyne (NASDAQ:TER) is a US-based supplier of automated test equipment for semiconductors as well as other technologies and devices.
Why Are We Cautious About TER?
- Products and services resonate with customers, evidenced by its respectable 5.3% annualized sales growth over the last five years
- Estimated sales growth of 24.4% for the next 12 months implies demand will slow from its two-year trend
- 6.2 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
At $382.63 per share, Teradyne trades at 38.1x forward P/E. If you’re considering TER for your portfolio, see our FREE research report to learn more.
West Pharmaceutical Services (WST)
Trailing 12-Month GAAP Operating Margin: 20.5%
Founded in 1923 and serving as a critical link in the pharmaceutical supply chain, West Pharmaceutical Services (NYSE:WST) manufactures specialized packaging, containment systems, and delivery devices for injectable drugs and healthcare products.
Why Does WST Give Us Pause?
- Annual revenue growth of 5.7% over the last five years was below our standards for the healthcare sector
- Costs have risen faster than its revenue over the last five years, causing its adjusted operating margin to decline by 5.3 percentage points
- Shrinking returns on capital suggest that increasing competition is eating into the company’s profitability
West Pharmaceutical Services is trading at $337.11 per share, or 36.4x forward P/E. To fully understand why you should be careful with WST, check out our full research report (it’s free).
Viavi Solutions (VIAV)
Trailing 12-Month GAAP Operating Margin: 6.9%
Once known as JDS Uniphase before its 2015 rebranding, Viavi Solutions (NASDAQ:VIAV) provides testing, monitoring and assurance solutions for telecommunications, cloud, enterprise, military, and other critical networks and infrastructure.
Why Does VIAV Worry Us?
- 4.8% annual revenue growth over the last five years was slower than its industrials peers
- Expenses have increased as a percentage of revenue over the last five years as its operating margin fell by 7.4 percentage points
- Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value
Viavi Solutions’s stock price of $38.75 implies a valuation ratio of 23.6x forward P/E. Check out our free in-depth research report to learn more about why VIAV doesn’t pass our bar.
Stocks We Like More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.